52 results about "Brain targeting" patented technology

The invention provides a ziconotide nasal-brain delivery preparation which is high in brain targeting, safe and noninvasive and directly enters the brain through nasal administration. The nasal-brain delivery preparation comprises an active component ziconotide and an absorption enhancer, wherein the absorption enhancer is selected from one or more of dodecyl-beta-D-maltoside (DDM), menthol, hydroxypropyl-beta-cyclodextrin (HP-beta-CD), sodium glycocholate (SGC) and related derivatives thereof. The absorption enhancer with a specific type and content and the ziconotide cooperate and act together, so that the ziconotide bypasses a blood brain barrier, enters the brain through a nasal olfactory mucous membrane, forms a medicine storage bank in an olfactory bulb, is slowly released to the brain and keeps a long-term medicine effect, and therefore, a traditional ziconotide intrathecal administration mode is abandoned; the ziconotide nasal-brain administration mode is created, and the ziconotide nasal-brain administration method is a new-generation therapy for pain diseases related to the central nervous system.

The invention discloses design and synthesis of a series of brain-targeted ginsenoside Rg1 derivatives and application of the brain-targeted ginsenoside Rg1 derivatives in treatment of Alzheimer's disease. According to the invention, ginsenoside Rg1 and polyethylene glycol with a specific chain length are covalently linked to successfully construct the derivative capable of enhancing the penetrating power of the blood-brain barrier. The series of derivatives provided by the invention not only solve the problems of poor brain targeting and insufficient stability of natural Rg1, but also can inhibit neuroinflammation by regulating and controlling an NLRP3 / caspase-1 signal channel in an LPS-induced neuroinflammation model, and finally, the learning and memory ability is remarkably improved. The product is simple and convenient in preparation process and good in biological safety, and a new candidate compound is provided for developing a new generation of Alzheimer disease treatment medicines.

The invention provides a nomeline nasal-brain delivery preparation for transnasal region mucosa administration, and an auxiliary material mixture of the nasal-brain delivery preparation comprises 1) phospholipid, and 2) any one of diluent ethyl oleate, isopropyl myristate, sesame oil or castor oil; optionally, the auxiliary material mixture can also comprise 3) a dissolving agent such as ethanol or diethylene glycol monoethyl ether, the auxiliary material mixture is a non-aqueous system, and a solution prepared from the mixture of the two or three auxiliary materials can be absorbed by the nasal meatus olfactory mucosa after being administrated through the nasal region mucosa, can be quickly conducted to the brain olfactory bulb region along olfactory nerves and cerebrospinal fluid, and can be used for treating the brain olfactory bulb. The problems that the peripheral side effect is high due to poor brain targeting of the medicine, the medicine takes effect slowly and the like are solved.

The invention relates to a bionic nano CO generator as well as preparation and application thereof, belongs to the technical field of medicines, and solves the problem that a CO delivery system which can synergistically promote neuroprotection and neurogenesis and has brain targeting and controlled release capabilities is urgently required to be developed at present. According to the technical scheme, the bionic nano CO generator comprises a drug-loaded particle inner core and a covering film, the drug-loaded particle inner core comprises hollow mesoporous CeO2 nano particles and MnCO loaded on the hollow mesoporous CeO2 nano particles, and the covering film is a macrophage membrane and wraps the drug-loaded particle inner core. The compound is used for apoplexy treatment administration by integrating neuroprotection and enhancing innovative dual channels of endogenous nerve growth, and is expected to significantly reduce brain injury after cerebral apoplexy and restore neurological functions so as to relieve the worry about high death rate and long-term disability after cerebral ischemia-reperfusion injury.

The invention provides a POCD treatment medicine composition with dendrobine delivered by a nano-carrier and application, and belongs to the technical field of medicine. The composition consists of dendrobine, a nano-carrier material and a stabilizer, wherein a nano-carrier is PLGA (poly (lactic-co-glycolic acid)) nanoparticles or lipidosome. The particle size of the composition is 50-150nm, the polydispersity index is less than 0.3, and the loading capacity of dendrobine is 5-15%. The invention also provides two preparation methods of the composition. The PLGA nanoparticles are prepared by adopting an emulsification-solvent evaporation method; the liposome is prepared by adopting a film hydration-ultrasonic extrusion method, and each process parameter is specifically limited. The pharmaceutical composition can significantly improve the brain targeting and bioavailability of dendrobine, and can be used for preparing drugs for preventing or treating postoperative cognitive impairment (POCD), and the administration route can be intravenous injection or nasal administration.

The invention relates to an anti-epileptic polypeptide coupling medicine and a preparation method and application thereof, the polypeptide coupling medicine comprises an Fmoc protecting group, a permeation accelerating peptide and a cell penetrating peptide which are sequentially connected from the N end to the C end, and the permeation accelerating peptide is connected with an anti-epileptic medicine molecule. According to the invention, by fully utilizing the treatment requirements of epileptic seizure and the technical advantages of intranasal drug delivery, through the collaborative design of the protecting group, the functional polypeptide sequence and the anti-epileptic drug, the defects of poor brain targeting property, easy cyclization of a polypeptide carrier, low intranasal delivery efficiency and the like of the traditional anti-epileptic drug are overcome, non-invasive, efficient and low-toxicity epilepsy treatment is realized, and the application prospect is wide. And the preparation process is simplified, the clinical transformation requirement is met, and meanwhile, a new strategy is provided for non-invasive brain delivery of neuropeptide drugs.

The invention provides a biotinylated Angiopep-2 modified targeting nano material as well as a preparation method and application of the biotinylated Angiopep-2 modified targeting nano material. According to the preparation method of the biotinylated Angiopep-2 modified targeting nano-material, Angiopep-2 is directionally anchored through a high-affinity biotin-streptavidin system, ligand conformation inactivation caused by chemical coupling is avoided, targeting activity is maintained, the used Angiopep-2 can help nanoparticles to be specifically recognized and combined and mediate the nanoparticles to cross a blood brain barrier to enter the brain, and the targeting nano-material can be used for preparing the targeted nano-material. The drug concentration in brain tissues is increased, so that the cure rate of brain diseases is improved, the brain targeting efficiency is far higher than that of transferrin and lactoferrin, and the application value is great; by entrapping curcumin and quercetin, a hydrophilic shell is provided, so that the water solubility of curcumin and quercetin is improved, and the bioavailability of curcumin and quercetin is improved.

The invention discloses a brain-targeted nasal-spray amphotericin B phospholipid complex and a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations, the brain-targeted nasal-spray amphotericin B phospholipid complex is prepared by adopting a film dispersion method, and the preparation method comprises the following steps: dissolving 15-hydroxystearic acid polyethylene glycol ester, phospholipid, cholesterol, amphotericin B and optional other auxiliary components in a solvent, removing the solvent until a film is formed, and drying to obtain the brain-targeted nasal-spray amphotericin B phospholipid complex. And carrying out hydration dispersion to obtain the amphotericin B-loaded phospholipid complex. According to the amphotericin B sodium deoxycholate injection, the problems that the traditional amphotericin B sodium deoxycholate injection is high in renal toxicity, the intrathecal injection is poor in solubility, and low in bioavailability and patient compliance, large in side effect and the like due to the fact that the traditional amphotericin B sodium deoxycholate injection is difficult to penetrate through a blood brain After nasal administration, the drug is quickly delivered into the brain, so that the slow release of the drug is realized, the intracerebral bioavailability of the drug is improved, high brain targeting and low systemic toxic and side effects are realized, and good clinical application value and market prospect are achieved.

The application discloses a preparation method of a novel hierarchical drug release lemon exosome nano preparation and application thereof in brain glioma treatment and belongs to the field of nano medicines. The method comprises the following steps: extracting and purifying lemon exosomes, introducing an anti-glioma drug and a first part of LRP1 up-regulating agent into the inner cavity of the exosomes through electroporation, instantaneously constructing a tumor microenvironment responsive nanogel core to fix the drug, embedding a second part of LRP1 up-regulating agent into the lipid layer of the exosome, modifying Angiopep-2 to realize brain targeting, and obtaining the nano preparation through purification. The preparation has the hierarchical drug release characteristics of outer layer early release and inner cavity delayed release, can improve the efficiency of drug crossing the blood-brain barrier and accumulation at the tumor site, enhance the anti-glioma effect, solves the technical problem that the existing drug loading system is difficult to realize multi-drug phased release, and provides a new strategy for brain glioma treatment.

The invention discloses a temozolomide spherocrystal based on nano confinement crystallization regulation and a method and application thereof. The preparation method of the temozolomide spherocrystal based on nano confinement crystallization regulation and control comprises the following steps: dissolving glycyrrhizic acid and temozolomide in pure water under an ultrasonic condition, adjusting the pH value to 3-4, heating until the solution is clear, and cooling to 0-5 DEG C under a stirring condition to obtain the temozolomide spherocrystal based on nano confinement crystallization regulation and control. Compared with the temozolomide raw material I crystal form, the temozolomide spherocrystal disclosed by the invention shows excellent nasal administration characteristics, including uniform particle size, high sphericity and excellent fluidity. Cell experiments show high cytotoxicity (IC50 = 51.9 [mu] g mL <-1 >) to glioblastoma, and in vivo experiments prove efficient brain targeting ability of the polypeptide. The preparation method has the characteristics of mild preparation conditions, easiness in process control, good reproducibility, high brain targeting property and the like, and is suitable for treating cancers delivered into the brain through the nose.

The invention discloses a traditional Chinese medicine monomer nanoparticle oral delivery system based on intestinal liver circulation and a preparation method thereof, spherical nanoparticles (SA NPs) with the particle size of 194 + / -20 nm are formed through self-assembly of threat resin acid (SA), and the limitation of a traditional nano carrier is broken through: the oral bioavailability reaches 34.7% by utilizing an ASBT-mediated intestinal liver circulation mechanism; the gastric acid environment is tolerated (the pH is stable at 1.5), and after penetrating through the intestinal epithelium, the drug is targeted to ischemic brain tissues; the medicine has carrier-medicine dual functions, and the cerebral infarction volume is reduced by 34.1% when the medicine is singly used; after the neuroprotective peptide NA1 is loaded (the drug loading capacity is 5.8 wt%), the infarct volume is reduced by 68.7% through synergism. The system is suitable for pre-hospital first aid of cerebral apoplexy, and the freeze-dried powder can be stored at normal temperature for 12 months. The delivery system has a great application prospect in preparation of drugs for treating acute ischemic stroke needing rapid brain targeting.

The invention belongs to the technical field of biological medicine, and particularly relates to a nano-micelle preparation loaded with minocycline and application of the nano-micelle preparation to treatment of cerebral hemorrhage, the nano-micelle preparation is prepared by taking a polyethylene glycol-polycaprolactone nano material PEG3000-PCL2000 as a carrier, and jointly loading minocycline MINO and a CD147 monoclonal antibody Anti-CD147, so that the nano-micelle preparation is prepared. And the bionic nano-drug MINO (at) PNM (at) CD147 with an active targeting function is constructed. The nano-micelle preparation has a brain targeting property and can be enriched in cerebral hemorrhage tissues, so that the local drug concentration and the treatment efficiency are remarkably improved; the traditional Chinese medicine composition can improve neurological impairment caused by cerebral hemorrhage and significantly reduce the volume of cerebral hematoma, and has an obvious treatment effect on cerebral hemorrhage; the number of inflammatory cells in the peripheral area of hematoma and expression of inflammatory mediators can be remarkably reduced, and therefore the inflammatory response in cerebral hemorrhage tissue is relieved.

The application discloses application of RVG-Exo-miR-3059-5 in treating cerebral stroke. The RVG-Exo-miR-3059-5 is prepared by using gene engineering technology to perform brain targeting modification on EPCs-Exo and load miR-3059-5p drugs. The experiment proves that the RVG-Exo-miR-3059-5 can effectively target brain tissues, can prevent or treat cerebral stroke, and can improve the prognosis of cerebral stroke patients.

The invention discloses a proteolysis targeting chimeric molecule capable of degrading PTBP1 in a targeting manner as well as a preparation method and application of the proteolysis targeting chimeric molecule. The invention relates to a protease targeted chimeric RNA-PTAC of a nucleic acid ligand. The protease targeted chimeric RNA-PTAC is formed by connecting an E3 ubiquitin ligase ligand pomalidomide and an RNA fragment capable of being specifically combined with PTBP1 protein through polyethylene glycol Linker. The invention relates to an RNA-PROTAC (Ribonucleic Acid-PROTAC) brain targeting delivery preparation, which is a complex obtained by coupling cell penetrating peptides TAT and RVG (Recombinant Virus Growth) with the RNA-PROTAC. According to the TR + RNA-PROTAC complex disclosed by the invention, the targets of efficiently degrading PTBP1 protein in vitro and degrading PTBP1 protein in a brain in a targeted manner in vivo are achieved through the complex, and in-vivo experiments also prove that the TR + RNA-PROTAC complex can be used for treating learning and memory disorders of mice caused by A beta and shows a good curative effect of resisting Alzheimer's disease.

The invention belongs to the field of fluorescent probes, and discloses a selenium cyano fluorescent probe for high-selectivity recognition of H2S as well as a preparation method and application of the selenium cyano fluorescent probe. The probe adopts dicyanoisophorone as a fluorophore skeleton and-SeCN group as a novel recognition site, and the structural formula is shown in the specification. The dicyanoisophorone has relatively large Stokes shift during release, so that the interference of autofluorescence on signal detection is reduced, and the dicyanoisophorone is connected with a-SeCN group through a condensation reaction. On the basis of a double nucleophilic substitution strategy, H2S induces conversion of-SeCN into-Se-S, and near-infrared fluorophores are released through intramolecular self-cyclization. Researches show that the probe has high sensitivity, selectivity, good water solubility and thiol consumption resistance, the detection limit is as low as 20 nM, and the probe has good ratio signal and brain targeting ability.

This invention relates to an insoluble drug formulation based on dialkylimidazolium biomimetic lipids, its preparation method, and its application, belonging to the field of pharmaceutical formulations. First, an insoluble drug is directly coupled to the primary amine group of the dialkylimidazolium biomimetic lipid or coupled via a linker to form a lipid-drug conjugate. Then, the lipid-drug conjugate, along with other lipid excipients, is dissolved in the dialkylimidazolium biomimetic lipid, and self-assembled in an aqueous phase to form a drug-loaded lipid nanoparticle delivery system with significant drug solubilizing effect. This drug delivery system exhibits good biocompatibility and plasma stability. It can cross the blood-brain barrier and selectively deliver drugs to glioma cells, achieving sustained release of the conjugated insoluble drug in the tumor microenvironment. This provides a new strategy for improving the pharmacokinetic properties of insoluble small-molecule antitumor drugs, including brain targeting, half-life, and bioavailability.

The invention discloses a blood-brain barrier crossing nucleic acid drug delivery system based on glycosyl functional nucleic acid and a preparation method and application thereof, and belongs to the technical field of biomedicine. The core of the system is a glycosylated transferrin receptor aptamer (GTA), and the GTA is formed by covalently linking a glycosyl modification module and a transferrin receptor binding sequence and can be combined with therapeutic nucleic acid to form a compound. According to the invention, the blood-brain barrier crossing efficiency and brain targeting property of nucleic acid drugs are remarkably improved through a dual-channel synergistic mechanism formed by transferrin receptor mediated transfection and glucose transporter assisted uptake; the GTA can be automatically prepared through a DNA solid-phase synthesis platform, and is controllable in structure, stable in batch, high in biocompatibility and low in immunogenicity. The delivery system can be compatible with multiple nucleic acid drugs such as siRNA, ASO and CpG ODN, and has a wide application prospect in treatment of central nervous system diseases such as glioblastoma.

The invention discloses an exosome-like nano-vesicle derived from rhizoma acori graminei as well as a preparation method and application of the exosome-like nano-vesicle. The rhizoma acori graminei-sourced exosome-like nano-vesicle contains rich bioactive components, has excellent biocompatibility, brain targeting property and cross-biological barrier property, and is beneficial to enhancing the treatment effect of brain diseases. After oral administration or caudal vein injection, the exosome-like nano-vesicle derived from the rhizoma acori graminei can enter the brain across the blood brain barrier, the behavioral disorder of AD model mice is improved, the disease development of Alzheimer's disease cognitive impairment accompanied by depression is improved through the effects of relieving neuron injury, neuroinflammation and synaptic injury, and the development of Alzheimer's disease cognitive impairment accompanied by depression is promoted. Wide application prospects are shown.

The invention discloses a Chinese yam-derived exosome-like nano-vesicle as well as a preparation method and application of the Chinese yam-derived exosome-like nano-vesicle. The Chinese yam-derived exosome-like nano-vesicle disclosed by the invention has excellent biocompatibility, drug treatment capability, brain targeting property and transmembrane property, and is beneficial to enhancing the treatment effect. The Chinese yam-sourced exosome-like nano-vesicle disclosed by the invention is combined with a nasal administration route, so that the blood-brain barrier can be spanned, the medicine is directly conveyed to the brain, and the treatment effect of the Chinese yam-sourced exosome-like nano-vesicle in Parkinson's disease is promoted through neuroprotection and anti-oxidative damage effects. A new thought is provided for application of Chinese yam in modern medicine, combination of traditional Chinese medicine and emerging technologies is promoted, and wide application prospects are shown.

The invention discloses a targeted delivery preparation as well as a preparation method and application thereof, and belongs to the technical field of biology and new medicine. The targeted delivery preparation comprises an agent A and an agent B in a ratio of (0.1-0.3) g: (2-5) mL; the agent A comprises nasal brain targeting peptide modified stem cell factor liposome freeze-dried powder and gel dry powder, the amino acid sequence of the nasal brain targeting peptide is as shown in SEQ ID NO.1, and the gel dry powder is formed by self-crosslinking mangiferin and rutin; and the agent B is a normal saline solution containing carboxymethyl chitosan. The targeted delivery preparation not only can meet long-time stable storage, but also can enhance the nasal-brain delivery efficiency of stem cell drugs. Besides, the targeted delivery preparation can be used independently or in combination with other treatment drugs, and is used for treating ischemic cerebral diseases, especially cerebral arterial thrombosis.

The invention relates to a bionic nano delivery platform for brain targeting and photothermal therapy, a preparation method of the bionic nano delivery platform and application of the bionic nano delivery platform in treatment of neurodegenerative diseases. The platform is composed of a drug-loading core and a functionalized shell, wherein the drug-loading core is a cycloastragenol-loaded liposome; the functionalized shell covers the drug loading core and is composed of a microcolloid cell membrane and a near-infrared two-region photo-thermal material dispersed in the microcolloid cell membrane. According to the structure, through cell membrane bionic modification, a platform is endowed with good brain focus targeting, efficient immune escape ability and a remarkable drug enrichment effect, and collaborative delivery and controlled release of cycloastragenol and a photo-thermal material can be achieved. The platform and the system have the comprehensive advantages of being accurate in brain targeting, remarkable in treatment synergistic effect and good in biocompatibility, and have wide clinical application prospects in the field of targeted therapy of neurodegenerative diseases.

The present application relates to the field of biological medical technology, and more particularly to specific MGMT polypeptide, its antibody and application in clinic. The present application obtains polypeptide combination for malignant glioma prediction by screening after imbricate cutting, and then uses MGMT-02 and MGMT-04 in the polypeptide combination to prepare monoclonal antibody; the monoclonal antibody is coupled with TAT cell-penetrating peptide, and then is complexed with cell nanometer iron oxide particles, so that the complex formed can be used for reversing TMZ drug resistance by targeting intranuclear MGMT of TMZ drug-resistant GBM cell line under the premise of solving brain targeting delivery, and provides a new solution for developing targeted synergistic therapy for TMZ drug-resistant GBM in clinic, and has important translational medicine value and great industrialization potential.

The invention discloses a preparation method of a high-loading-capacity brain-targeting-enhanced exosome, a product and application, and belongs to the technical field of biological medicine. The invention aims to solve the technical problems of low targeting peptide expression quantity, insufficient loading rate, poor targeting efficiency, weak blood brain barrier penetrating power and the like in the existing exosome targeting modification technology. According to the technical scheme, the method is characterized in that the concentration ratio of DBCO-NHS to T7 to exosome is optimized, and the high loading rate is achieved through a two-step loading system.

This invention relates to an enzyme-responsive brain-targeting sustained-release formulation based on dialkylimidazolium biomimetic lipids, its preparation method, and its application, belonging to the field of drug delivery. First, dialkylimidazolium biomimetic lipids are covalently coupled with natural phospholipids to form a dialkylimidazolium conjugate. Then, this dialkylimidazolium conjugate is self-assembled with dialkylimidazolium biomimetic lipids, natural phospholipids, cholesterol, and a therapeutic drug to form a drug-loaded lipid nanoparticle delivery system. This drug delivery system can effectively cross the blood-brain barrier to achieve brain-targeted delivery of the loaded drug. In the glioma microenvironment, this drug delivery system can gradually hydrolyze the dialkylimidazolium conjugate through an enzyme-responsive mechanism to achieve sustained release of the loaded drug, providing a new strategy for improving the brain targeting and efficacy of different types of anti-glioma drugs, such as small nucleic acid drugs, peptide drugs, and small molecule drugs.

The invention discloses a medicine for treating neurodevelopment disorder diseases. The invention provides a etiological treatment method capable of crossing a blood brain barrier and directly targeting neural synaptic function repair, stable expression of an exogenous TBL1XR1 gene in a plurality of key brain regions (including hippocampus, prefrontal lobe, basal ganglion and the like) can be realized, and the TBL1XR1 gene has good brain targeting property and tissue affinity, and can be applied to the field of brain diagnosis and treatment. The synaptic disorder in the nervous system and the related nerve development process can be improved, and the composition has good safety in the aspects of system and nerve immunity. The application opens up a new intervention path for the neurodevelopment disorder diseases, especially the neurodevelopment disorder diseases caused by TBL1XR1 gene mutation.

The invention belongs to the technical field of biological medicines, and relates to a bionic nano-enzyme composition for inhibiting ferroptosis and relieving excitatory toxicity as well as preparation and application of the bionic nano-enzyme composition. The biomimetic nano-enzyme composition disclosed by the invention consists of platinum nano-enzyme and lactoferrin, and can effectively relieve cerebral ischemia-reperfusion injury and play a role in neuroprotection by inhibiting ferroptosis and relieving excitatory toxicity. The biomimetic nano-enzyme composition disclosed by the invention can be used for remarkably enhancing active oxygen removal and inflammation regulation capabilities of platinum nano-enzyme as well as in-vivo brain targeting and permeability, and finally, the treatment effect on cerebral ischemia reperfusion injury is effectively improved. The biomimetic nano-enzyme composition disclosed by the invention combines active oxygen and ammonium ion removal activity of platinum nano-enzyme and iron chelation and brain targeting capabilities of lactoferrin, realizes multi-target and multi-path treatment, and effectively improves the treatment effect of cerebral ischemia-reperfusion injury.

The invention discloses a method for regulating and controlling beta-amyloid protein aggregation based on circularly polarized light and application of the method, and the method comprises the following steps: adding amino-modified up-conversion luminescent nanoparticles into a SiO2-coated chiral optical activity nanostructure for electrostatic binding to obtain an up-conversion chiral nano functional material; the method comprises the following steps: coating the surface of an upconversion chiral nano functional material with a biocompatible coating and a brain-targeting ligand, mixing the upconversion chiral nano functional material with beta-amyloid protein, applying 800-1400 nm laser irradiation to a targeting region at 5-100 mW / cm < 2 > for 15-30 minutes, exciting the upconversion chiral nano functional material to emit circularly polarized light, and forming the circularly polarized light by interfering beta-folded conformation of the beta-amyloid protein, therefore, the aggregation of the beta-amyloid protein is inhibited. Circularly polarized light (CPL) is utilized to induce interaction change of protein key sites, so that conformation of protein aggregation is changed, and the process has reversibility and high spatial selectivity; animal experiments prove that the method can effectively block Abeta aggregation and improve the cognitive function.

The application discloses a cannabinoid 1 type receptor-mediated brain-targeting lipid nanocapsule drug loading system and a preparation and application thereof, and belongs to the technical field of targeted drugs. The brain-targeting lipid nanocapsule drug loading system comprises a drug-loaded lipid nanocapsule, the surface of the lipid nanocapsule is modified with a ligand compound of a CB1 receptor, and the ligand compound is one of quebrachamine, methoxylated myristicin, chelerythrine, ostruthol or cannabigerol. The application utilizes the lipid nanocapsule carrier to load a compound X with neuroprotective activity, prolongs the circulation time of the compound X in the body, adsorbs a ligand compound Y on the surface of the lipid nanocapsule, can specifically recognize the CB1 receptor highly expressed on the brain nerve epidermal cells, can transport across the blood-brain barrier, and improves the drug concentration in the brain tissue and cells. The preparation method provided by the application is simple in operation, easy to popularize, can be used for preparing drugs crossing the blood-brain barrier, and has a wide application prospect.

The present application provides a kind of drug composition and its application for targeting neuroinflammation, the composition is composed of active ingredient and natural nanometer delivery carrier for encapsulating active ingredient, the active ingredient includes fisetin, pyrrole quinoline quinone, resveratrol, bauhinia A, apigenin, saffron, quercetin and hair monkey element;The natural nanometer delivery carrier is the plant source extracellular vesicle of surface modification brain targeting molecule.The composition of the present application realizes the intervention to vascular cognitive impairment by multi-component scientific compatibility, combined with two-stage brain targeting delivery design, solves the pain points of low blood-brain barrier penetration rate and poor bioavailability of natural active ingredient, has the effect of strong anti-inflammatory and significantly improving cognitive function, excellent safety, can be used for preparing the medicine for preventing or adjuvant therapy neuroinflammation related vascular cognitive impairment, has very high clinical conversion value.

The invention discloses lipid nanoparticles for realizing brain targeting through a nasal cavity way as well as a delivery method and application of the lipid nanoparticles. The lipid nanoparticles are prepared from the following raw materials: peptidyl ionizable lipid, auxiliary phospholipid, steroidal lipid and polyethylene glycol lipid, wherein the structural formula of the peptidyl ionizable lipid is as shown in formula I, and the peptidyl ionizable lipid accounts for 45-65% of the total lipid in mole percentage; the auxiliary phospholipid accounts for 10-20 mol% of the total lipid, the steroidal lipid accounts for 30-50 mol% of the total lipid, and the polyethylene glycol lipid accounts for 1-5 mol% of the total lipid. And wrapping nucleic acid molecules in the lipid nanoparticles to form the lipid nanoparticles entrapped with nucleic acid. According to the invention, a non-invasive and efficient brain-targeted mRNA delivery platform is established, and a solid foundation is laid for expanding the application of mRNA therapy in the field of nerves.